Richard Thomas Meehan

Dr. Richard Thomas Meehan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RMRichard Thomas Meehan
Richard Thomas Meehan
ERElizabeth A. Regan
Elizabeth A. Regan
EHEric D. Hoffman
Eric D. Hoffman
MWMolly L. Wolf
Molly L. Wolf
MGMary T. Gill
Mary T. Gill
VKVijaya Knight
Vijaya Knight
Background: There are currently no effective disease-modifying drugs to prevent cartilage loss in osteoarthritis and synovial fluid is a potentially valuable source of biomarkers to understand the pathogenesis of different types of arthritis and identify drug responsiveness. The aim of this study was to compare the differences between SF cytokines and other proteins in patients with OA (n = 21) to those with RA (n = 27) and normal knees (n = 3). Methods: SF was obtained using ultrasound (US) guidance and an external pneumatic compression device. RA patients were categorized as active (n = 20) or controlled (n = 7) based upon SF white blood cell counts (> or <300 cells/mm3). Samples were cryopreserved and analyzed by multiplex fluorescent bead assays (Luminex). Between-group differences of 16 separate biomarker proteins were identified using ANOVA on log10-transformed concentrations with p values adjusted for multiple testing. Results: Only six biomarkers were significantly higher in SF from active RA compared to OA—TNF-α, IL-1-β IL-7, MMP-1, MMP-2, and MMP-3. Only MMP-8 levels in RA patients correlated with SF WBC counts (p < 0.0001). Among OA patients, simultaneous SF IL-4, IL-6, IL-8, and IL-15 levels were higher than serum levels, whereas MMP-8, MMP-9, and IL-18 levels were higher in serum (p < 0.05). Conclusion: These results support the growing evidence that OA patients have a pro-inflammatory/catabolic SF environment. SF biomarker analysis using multiplex testing and US guidance may distinguish OA phenotypes and identify treatment options based upon targeted inflammatory pathways similar to patients with RA.

29 July 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
RMRichard Thomas Meehan
Richard Thomas Meehan
IAIsabelle Anne Amigues
Isabelle Anne Amigues
VKVijaya Knight
Vijaya Knight
Despite the growing number of biologic and JAK inhibitor therapeutic agents available to treat various systemic autoimmune illnesses, the lack of a validated companion diagnostic (CDx) to accurately predict drug responsiveness for an individual results in many patients being treated for years with expensive, ineffective, or toxic drugs. This review will focus primarily on rheumatoid arthritis (RA) therapeutics where the need is greatest due to poor patient outcomes if the optimum drug is delayed. We will review current FDA-approved biologic and small molecule drugs and why RA patients switch these medications. We will discuss the sampling of various tissues for potential CDx and review early results from studies investigating drug responsiveness utilizing advanced technologies including; multiplex testing of cytokines and proteins, autoantibody profiling, genomic analysis, proteomics, miRNA analysis, and metabolomics. By using these new technologies for CDx the goal is to improve RA patient outcomes and achieve similar successes like those seen in oncology using precision medicine guided therapeutics.

15 January 2019 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
PDF file
RMRichard Thomas Meehan
Richard Thomas Meehan
CWChris Wilson
Chris Wilson
EHEric Hoffman
Eric Hoffman
LALynne Altimier
Lynne Altimier
MKMaryanne Kaessner
Maryanne Kaessner
ERElizabeth A. Regan
Elizabeth A. Regan

25 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RMRichard Thomas Meehan
Richard Thomas Meehan
MGMary T. Gill
Mary T. Gill
EHEric D. Hoffman
Eric D. Hoffman
CCClaire Coeshott
Claire Coeshott
MGManuel Galvan
Manuel Galvan
VKVijaya Knight
Vijaya Knight
Background: Prior studies have demonstrated improved efficacy when intra-articular (IA) therapeutics are injected using ultrasound (US) guidance. The aim of this study was to determine if clinical improvement in pain and function after IA hyaluronic acid injections using US is associated with changes in SF volumes and biomarker proteins at 3 months. Methods: 49 subjects with symptomatic knee OA, BMI < 40, and KL radiographic grade II or III participated. Subjects with adequate aspirated synovial fluid (SF) volumes received two US-guided IA-HA injections of HYADD4 (24 mg/3 mL) 7 days apart. Clinical evaluations at 3, 6, and 12 months included WOMAC, VAS, PCS scores, 6 MWD, and US-measured SF depth. SF and blood were collected at 3 months and analyzed for four serum OA biomarkers and fifteen SF proteins. Results: Statistical differences were observed at 3, 6, and 12 months compared to baseline values, with improvements at 12 months for WOMAC scores (50%), VAS (54%), and PCS scores (24%). MMP10 levels were lower at 3 months without changes in SF volumes, serum levels of C2C, COMP, HA, CPII, or SF levels of IL-1 ra, IL-4, 6, 7, 8, 15, 18, ILGFBP-1, 3, and MMP 1, 2, 3, 8, 9. Baseline clinical features or SF biomarker protein levels did not predict responsiveness at 3 months. Conclusions: Clinical improvements were observed at 12 months using US needle guidance for IA HA, whereas only one SF protein biomarker protein was different at 3 months. Larger studies are needed to identify which SF biomarkers will predict which individual OA patients will receive the greatest benefit from IA therapeutics.

25 December 2024 in Arthritis Care & Research
Verified
Journal Article
Closed access
NGNishant Gupta
Nishant Gupta
SCSteven E. Carsons
Steven E. Carsons
NCNancy L. Carteron
Nancy L. Carteron
RSRobert Hal Scofield
Robert Hal Scofield
ALAugustine S. Lee
Augustine S. Lee
KHKatherine Hammitt
Katherine Hammitt